Navigating Regulatory Approval of Biologics: A Guide for Emerging Biotechs

• Bringing a biologic to market is an increasingly complex task, especially for small and mid-sized biotech companies with limited regulatory infrastructure.
• Meeting sometimes divergent EMA and FDA expectations, following increasingly complex regulations, and avoiding pitfalls related to documentation requires early planning and cooperation. Cross-functional alignment is also crucial to avoid issues related to comparability and process development/design space/process validation.
• This whitepaper outlines the key considerations in regulatory planning and biologics development, offering actionable insights for sponsors preparing their therapies for market.

Understanding the regulatory approval of biologics

Global regulatory agencies, particularly the EMA and the FDA, play a crucial role in safeguarding public health by establishing and enforcing rigorous standards. They aim to ensure that these advanced therapies are not only effective but also consistently produced and safe for patient use. Quality assurance and adherence to GMP compliance standards are critical requirements for any biologics CDMO manufacturing drugs for human use, with both EMA and FDA regulatory frameworks having precise requirements for assuring the quality of GMP operations.

For emerging biotech companies, following the complex and often divergent regulatory guidelines for biologics can represent a significant barrier to commercialization. Despite many similarities and widespread efforts to standardize regulatory processes, such as the adoption of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines and joint scientific meetings, significant differences do exist, creating numerous challenges for the pharmaceutical industry. Companies often need to prepare separate strategies, hire additional personnel and sometimes conduct further studies to satisfy the requirements of both agencies.

Yet, when managed strategically, a strong regulatory approach can also serve as a powerful accelerator, enabling faster market access and competitive advantage. The ICH guidelines play a crucial role in shaping the expectations of both the EMA and FDA, contributing to a high degree of convergence in their regulatory approaches for biologics. A comprehensive model for a pharmaceutical quality system, for instance, is specified in the globally harmonized ICH Q10 guideline. While the complexity of regulations continues to grow in parallel with the sophistication of new molecular entities being developed, ICH guidelines ensure that fundamental requirements remain relatively similar across the US and Europe. Therefore, engaging with regulatory experts and collaborating with experienced partners from the earliest stages of drug development is not merely beneficial but essential. This proactive strategy is the most effective way to anticipate and circumvent potential regulatory challenges, thereby streamlining the therapy’s journey to market and ultimately benefiting patients. It often involves a CDMO consulting a product dossier and previous regulator discussions to ensure compliance with relevant regulatory guidelines, including GMP and ICH.

The value of working with an experienced CDMO

For small and mid-sized biotech companies, dealing with the complex global regulatory guidelines for biologics can be a daunting task. Partnering with an experienced CDMO can provide a distinct advantage, significantly de-risking the development and approval process. Mabion’s background as a biologic developer and now a CDMO gives it unique insight from early-stage scientific advice to final marketing authorization submission and post-approval compliance. We support our partners throughout the entire regulatory cycle.

Working with an experienced CDMO like Mabion provides a proactive approach to risk management, including identifying and mitigating regulatory risks (such as incomplete CMC data or clinical trial delays) through scenario planning and risk analysis. Moreover, for regulatory inspections, Mabion can provide support for mock inspections and gap analyses as critical means to prepare a company for EMA/FDA inspection, ensuring a high level of preparedness and confidence. This comprehensive support empowers biotechs to confidently follow stringent regulatory requirements and accelerate the journey of innovative therapies to patients. We accelerate your regulatory approval of biologics.

FAQ

Prepared by:

Dorota Jaros

Regulatory and Validation Division Manager

d.jaros@mabion.eu

Dorota Jaros

Regulatory and Validation Division Manager

Dorota is the Head of Regulatory and Validation Department at Mabion S.A. She is responsible for ensuring quality and regulatory compliance across all areas of company’s activity including development, manufacturing and quality control of biological products. In her everyday work, she leads a large team of biotechnology and pharmacy specialists, whose tasks, among others, include preparation and submission of regulatory documentation, audit management and process validation. Her vast expertise and unwavering commitment to quality guarantee that Mabion’s services meet the highest standards of scientific and regulatory excellence.

Adam Tuszyner

Regulatory Compliance Specialist

a.tuszyner@mabion.eu

Adam Tuszyner

Regulatory Compliance Specialist

With a strong background in clinical pharmacology and evidence-based medicine, Adam specializes in regulatory science and clinical development for biologic drugs. He has authored and co-developed a wide range of regulatory documents, including FDA and EMA briefing materials and responses to agency queries. His career highlights include participation in pivotal scientific advices with regulators and involvement in biosimilar drug approvals.

References

1. ResearchAndMarkets.com, Biologics Strategic Research Report 2024-2030: Global Market to Reach $732.4 Billion – Collaborations and Partnerships Fueling Developments and Commercialization. 2025.
2. Tuszyner A, Malecka A. Similar but not the same: an in-depth look at the differences between EMA and FDA. Mabion Science Hub, 2025.
3. U.S. Food and Drug Administration. Applications for FDA Approval of a Biologic License (21 CFR Part 601). 2025.
4. European Medicines Agency, ICH Q14 on analytical procedure development. 2024.